20283 - Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Disease Types: Solid Tumors,&nbs

Available at: {clinical_trial_location backspace="7"}20283 - Ph2 Bren Vedo + Pembro ST prior PD-1, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}